At the IGTP TODAY
The organisations are collaborating on two studies in the field of severe Legionella infections and antibiotic resistance. Both projects have been presented by IGTP researchers within the framework of the "Scientific exchanges: join us" program, an initiative by Menarini to share progress and strengthen partnerships in research.
The report compiles the institution's key numbers and objectives, as well as its research activities. For the first time, the report also includes a web version that summarises the most relevant aspects.
Researchers from Barcelona's Germans Trias i Pujol Institute and Josep Carreras Leukaemia Research Institute have found a potential new way to improve the treatment of multiple sclerosis (MS) using a novel combined therapy. The results, published in the Journal of Clinical Investigation, builds on two harmonized Phase I clinical trials funded by the European Union, focusing on the use of Vitamin D3 tolerogenic dendritic cells (VitD3-tolDCs) to regulate the immune response in MS patients. The team is now preparing to move into Phase II trials to further explore these findings.
Several researchers from IGTP took part in this year's European Researchers' Night in Barcelona. They shared their passion for science through talks and led participants of a workshop via a board game into the midst of a tuberculosis epidemic.
Researcher Raquel Guillamat Prats discusses her research on respiratory diseases such as pulmonary fibrosis, respiratory infections, and lung cancer. She also shares her experience of establishing a research group from scratch at IGTP.
A new study, published in New England Journal of Medicine, has demonstrated the benefits of placing a clip on the valve instead of the usual medical treatment. The study includes the participation of Professor Antoni Bayés-Genís, principal investigator of the ICREC group and Director of the Heart Institute at Germans Trias Hospital.
_1725960548.jpg)
IGTP leading the first study in the world to prove that personalised therapies are more effective than classic drugs indicated for the treatment of this rare hormonal disease. It is based on response biomarkers that, depending on what they indicate, allow the best possible treatment to be assigned earlier. In addition to very noticeable facial and skeletal deformities, acromegaly causes severe alterations in other parts of the body. Published in The Journal of Clinical Endocrinology & Metabolism.
_1723033241.jpg)
This recognition consolidates the position of the IIS-IGTP as a reference centre in the management of biomedical research at the national level and ensures its status as an IIS for the next five years.
CMCiB celebrated its first five years of activity with a symposium dedicated to pioneering biomedical research at CosmoCaixa.
The Innomed Awards, held at the Can Ruti Campus, celebrated significant advancements in biomedical innovation and reinforced the commitment to collaboration among the leading healthcare and research institutions of this health ecosystem and its surroundings.
